TEVA · NYSE · STOCK
Teva Pharmaceutical Industries (TEVA) Stock Analysis
$36.37
52W $18.21 – $38.37
51/100
$42.35B
57.7
0.87
Is TEVA Bullish or Bearish?
Mixed.
Innellis AI committee rates Teva Pharmaceutical Industries Limited (TEVA) Watch with a composite score of 51/100
, based on 6 analysts with 50% agreement.
Last updated September 06, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +8.86 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -11.14 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Value Analyst remains cautious — p/e of 60.0 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- News sentiment is positive (+0.38 across 29 articles, 14d) — News
Bear Case
- P/E of 60.0 is expensive by classic value standards — Value
- Price-to-book of 4.8x prices in significant intangible value — Value
- Debt-to-equity of 2.12 adds balance-sheet risk to the value case — Value
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
- High leverage (debt-to-equity 2.12) amplifies downside in a stress scenario — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of September 06, 2026
Overall Committee Score
51/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 98%
of 192 Healthcare peers
Value Analyst
bearish
28
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− P/E of 60.0 is expensive by classic value standards
Growth Analyst
bearish
38
/ 100 · Moderate confidence
Growth story is weak, decelerating, or inconsistent
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst
bearish
30
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 2.12) amplifies downside in a stress scenario
Macro Analyst
bullish
80
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
bullish
70
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.38 across 29 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2704.43)
Investment Thesis Evolution
Committee score moved marginally from 51.1 to 51.1.
- New bearish signals: 1 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
Analyst-level changes:
- Value Analyst: +1 bearish signal(s).
Comparing 2026-09-05 to 2026-09-06 (1 day apart).
Technical Analysis
RSI (14)
46.2
Neutral
MACD Histogram
-0.210
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Support
$30.81
Resistance
$36.99
Bollinger %B
0.30
Inside Bands
Price vs Moving Averages
EMA 9
$36.74
Below
EMA 21
$36.36
Above
EMA 50
$35.26
Above
EMA 200
$31.50
Above
Fundamental Analysis
Valuation
46
Growth
19
Profitability
56
Financial Health
12
Cash Flow
70
Valuation
P/E Ratio
57.7×
P/B Ratio
5.47×
PEG Ratio
0.10
Dividend Yield
0.00%
52W High
$38.37
52W Low
$18.21
Quality & Growth
ROE
1782.6%
ROA
346.0%
Gross Margin
5245.8%
Operating Margin
1492.5%
Revenue Growth YoY
—
Debt / Equity
2.16
AI Fundamental Assessment
P/E ratio of 57.7 (rich relative to a 15-40x range); Price-to-book of 5.5x; PEG ratio of 0.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 17.8%; Return on assets of 3.5%; Net margin of 4.1%; Gross margin of 52.5%; Current ratio of 0.88 (tight short-term liquidity); Debt-to-equity of 2.16; Free cash flow per share is positive (2.04); Most recent quarter missed estimates by 92.1%; EPS growth decelerating (-44.8% -> -96.2% QoQ); Analyst estimates falling over recent quarters
Get the Full TEVA Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →